Breast Cancer

MinhTri Nguyen, MD, discusses why timely breast cancer care in rural areas is hindered by a "combination of burdens," including systemic policy issues.

Data from the phase 3 VERITAC-2 trial support the FDA approval of vepdegestrant in this breast cancer population.

Post-surgical treatment, functional gains were improved among patients with breast cancer.

The ODAC has noted there was no clinical benefit of camizestrant for patients with HR+/HER2– advanced or metastatic breast cancer with ESR1 mutation and radiographic progression.

Read this to learn 3 things you should know about the first-line treatment of mTNBC with TROP2-directed ADCs.

Sara Tolaney, MD, MPH, explored whether elacestrant can improve RFS vs standard endocrine therapy in patients with high-risk, ER+/HER2– early breast cancer.

New findings presented at the AACR Annual Meeting revealed risk factors for locoregional recurrence in patients diagnosed with breast cancer at age 40 or younger.

Surgical approach and adherence to endocrine therapy were predictors of locoregional recurrence in women diagnosed with breast cancer at age 40 or younger.

Explore how ADCs, ctDNA monitoring, and new endocrine options reshape metastatic breast cancer care, as well as sequencing and toxicity tips from experts.

Elizabeth Mittendorf, MD, discussed how the Clarity Breast AI algorithm can complement tools such as the Tyrer-Cuzick model to define breast cancer risks.

Elizabeth Mittendorf, MD, PhD, discusses Clarity Breast, an FDA-authorized AI tool that predicts 5-year breast cancer risk using standard 2D mammograms.

Young patients with breast cancer should always aim to advocate for themselves, said Shari Goldfarb, MD.

Elizabeth Mittendorf, MD, discussed how the Clarity Breast AI tool utilizes mammography to predict 5-year breast cancer risk.

Natalie Berger, MD, discusses the evolving landscape of ADC sequencing in breast cancer, the role of HER2 expression, and the "sandwich approach" to treatment.